MRC Human Immunology Unit, Medical Research Council (MRC) Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine (WIMM), John Radcliffe Hospital, University of Oxford, Oxford, UK, Oxford, UK.
F1000Res. 2020 Feb 25;9:145. doi: 10.12688/f1000research.22507.2. eCollection 2020.
The newly identified coronavirus known as 2019-nCoV has posed a serious global health threat. According to the latest report (18-February-2020), it has infected more than 72,000 people globally and led to deaths of more than 1,016 people in China. The 2019 novel coronavirus proteome was aligned to a curated database of viral immunogenic peptides. The immunogenicity of detected peptides and their binding potential to HLA alleles was predicted by immunogenicity predictive models and NetMHCpan 4.0. We report identification of a comprehensive list of immunogenic peptides that can be used as potential targets for 2019 novel coronavirus (2019-nCoV) vaccine development. First, we found 28 nCoV peptides identical to Severe acute respiratory syndrome-related coronavirus (SARS CoV) that have previously been characterized immunogenic by T cell assays. Second, we identified 48 nCoV peptides having a high degree of similarity with immunogenic peptides deposited in The Immune Epitope Database (IEDB). Lastly, we conducted a search of 2019-nCoV 9-mer peptides that i) bind to common HLA alleles in Chinese and European population and ii) have T Cell Receptor (TCR) recognition potential by positional weight matrices and a recently developed immunogenicity algorithm, iPred, and identified in total 63 peptides with a high immunogenicity potential. Given the limited time and resources to develop vaccine and treatments for 2019-nCoV, our work provides a shortlist of candidates for experimental validation and thus can accelerate development pipeline.
新鉴定的冠状病毒被称为 2019-nCoV,已对全球健康构成严重威胁。根据最新报告(2020 年 2 月 18 日),该病毒已在全球感染超过 72000 人,并导致中国 1016 多人死亡。将 2019 年新型冠状病毒蛋白组与经过精心整理的病毒免疫肽数据库进行比对。通过免疫预测模型和 NetMHCpan 4.0 预测检测到的肽的免疫原性及其与 HLA 等位基因的结合潜力。我们报告了鉴定出的一组综合免疫肽,可作为 2019 年新型冠状病毒(2019-nCoV)疫苗开发的潜在目标。首先,我们发现 28 个 nCoV 肽与先前通过 T 细胞检测鉴定为具有免疫原性的严重急性呼吸综合征相关冠状病毒(SARS CoV)相同。其次,我们鉴定出 48 个 nCoV 肽与免疫肽库中已有的免疫肽高度相似。最后,我们对 2019-nCoV 9 肽进行了搜索,这些肽:i)与中国人和欧洲人群中常见的 HLA 等位基因结合,ii)通过位置权重矩阵和最近开发的免疫原性算法 iPred 具有 TCR 识别潜力,共鉴定出 63 种具有高免疫原性潜力的肽。鉴于开发针对 2019-nCoV 的疫苗和治疗方法的时间和资源有限,我们的工作提供了候选药物的候选名单,用于实验验证,从而可以加速开发进程。